Amgen announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona. The abstracts showcase data from Amgen-sponsored and investigator-sponsored studies for colorectal, lung, prostate and gastric cancers using molecularly targeted modalities.  

“The breadth of these data reflects our strategy to advance diverse modalities for difficult-to-treat cancers,” said Jay Bradner, M.D., executive vice president, Research and Development, and chief scientific officer at Amgen. “These ESMO results underscore our leadership in oncology, contributing significant advancements with both investigational and established therapies. Guided by a deep understanding of cancer biology and leveraging incisive therapeutics, we can target dominant drivers of disease with unprecedented precision.”

HealthTech Insights: Bleichmar Fonti & Auld LLP Announces a Proposed Settlement in the In re Talis Biomedical Corporation Securities Litigation

Key presentations include:

  • First findings from the Phase 1b study of LUMAKRAS plus Vectibix in combination with FOLFIRI in first-line patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC).
  • Phase 1 dose escalation and initial dose expansion data from AMG 193 selected for a presidential symposium session.
  • First-in-human study of xaluritamig in men with metastatic castration-resistant prostate cancer (mCRPC).

For more information on the Amgen abstracts, see below.

HealthTech Insights: Egnyte Partners with Google Public Sector as Part of NIH STRIDES Initiative to Enhance Cloud Solutions for Biomedical Research

Abstracts and Presentation Times:

Amgen Sponsored Abstracts

LUMAKRAS® (sotorasib) plus Vectibix® (panitumumab)

  • Sotorasib (soto) + panitumumab (pani) and FOLFIRI in the first line (1L) setting for KRAS-G12C mutated metastatic colorectal cancer (mCRC): Safety and efficacy from the phase 1b CodeBreaK 101 study
    Abstract #505O, Proffered Paper Oral Session: 2, Madrid Auditorium – Hall 2, Sunday, September 15 from 3:05 – 3:15 p.m. CEST

AMG 193 

  • Phase 1 dose escalation and initial dose expansion results of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients (pts) with MTAP-deleted solid tumors
    Abstract #3482, Proffered Paper Oral Session: Presidential Symposium III: Eyes to the Future, Barcelona Auditorium – Hall 2, Monday, September 16 from 16:30 – 18:15 p.m. CEST

HealthTech Insights: Health In Tech Announces Closing of Initial Public Offering

Xaluritamig

  • Circulating tumor cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
    Abstract #1610P, Poster, September 15
  • Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a Phase 1 study
    Abstract #1598P, Poster, September 15

LUMAKRAS® (sotorasib) for NSCLC

  • Sotorasib long-term clinical outcomes in pre-treated KRAS G12C-mutated advanced NSCLC: pooled analysis from the CodeBreaK clinical trials
    Abstract #1305P, Poster, September 14
  • Clinical characteristics and therapeutic sequences of KRAS G12C advanced Non-Small Cell Lung Cancer (aNSCLC) patients (pts) treated by sotorasib in the French post-marketing authorization early access (post-MA EA)
    Abstract #1307P, Poster, September 14

HealthTech Insights: Designs For Health Inc. Held Liable For Infringement of Kaneka’s Ubiquinol Patent 

Bemarituzumab

  • Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression and biomarker overlap in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC)
    Abstract #1420P, Poster, September 16

Investigator Sponsored Studies

Vectibix® (panitumumab)

Prospective validation of the metastatic colon cancer score (mCCS) in patients with RAS wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE
Abstract #585P, Poster, September 16

HealthTech Insights: Casect Launches AI-Enhanced Case Log Platform for Surgeons

**mRNA profiling as a biomarker of prognosis and response to first-line treatment in metastatic colorectal cancer: discovery and validation of a gene expression signature in three randomized trials
Abstract #581P, Poster, September 16 

Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study
Abstract #517P, Poster, September 16

To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com

Source – prnewswire